LPAK细胞的增殖效应及其初步临床应用

用ＬＰＡＫ（ＬｙｍｐｈｏｋｉｎｅａｎｄＰＨＡＡｃｔｉｖｉａｔｅｄＫｉｌｌｅｒ）细胞／ＩＬ－２过继免疫疗法治疗１７例晚期肿瘤，在１２例可评估病例中，５例肝癌（包括转性肝癌１例）有３例肿瘤分别缩小３５．７％、３９．５％和４７．８％；２例肺癌和２例转移性肺癌治疗后肿瘤无明显变化；１例胃癌癌性腹水治疗后腹水大部消失；１例皮肤恶性淋巴瘤治疗后皮损消退５０％以上。

Preliminary Clinical Studies of Cancer LPAK/IL-2 Adoptive Immunotherapy

In the preliminary clinical study of LPAK (Lymphokine and PHA Activated Killer) /IL-2 ( In terleukin-2, IL-2), 17 patients with advanced carcinoma were treated with LPAK/L-2 adoptive immunotherapy, 12 of them were eligible, 2/4 of HCC had 35. 7% and 47. 8% tumor regression respectively. 1 metastatic liver cancer had 39. 5% tumor regression. The tumor regression of the cutaeous T cell lymphoma was more than 50%. We conclude that: LPAK/IL-2 has actual antitumor effects in clinical studies.